Table 7.
Occurrence of adverse drug reactions by safety specification category
| Safety specifications | Number of patients |
|---|---|
| Preferred term | |
| Acute hepatic failure and hepatic function disorder | 226 |
| Acute hepatic failure | 1 |
| Alanine aminotransferase abnormal | 1 |
| Alanine aminotransferase increased | 9 |
| Aspartate aminotransferase abnormal | 1 |
| Aspartate aminotransferase increased | 11 |
| Gamma-glutamyltransferase increased | 15 |
| Hepatic function abnormal | 136 |
| Hepatic steatosis | 1 |
| Hepatitis acute | 1 |
| Hyperbilirubinaemia | 2 |
| Liver disorder | 50 |
| Liver function test abnormal | 2 |
| Transaminases increased | 1 |
| Hepatic enzyme increased | 11 |
| Drug-induced liver injury | 5 |
| Hepatic cancer | 1 |
| Liver function test increased | 3 |
| Thirst | 133 |
| Lip dry | 1 |
| Thirst | 133 |
| Hypernatraemia | 81 |
| Blood sodium increased | 7 |
| Hypernatraemia | 74 |
| Renal failure and impairment | 80 |
| Azotaemia | 0 |
| Blood creatinine increased | 18 |
| Blood urea increased | 14 |
| Glomerular filtration rate decreased | 2 |
| Renal disorder | 2 |
| Renal failure | 11 |
| Protein urine present | 1 |
| Postrenal failure | 1 |
| Renal impairment | 36 |
| Chronic kidney disease | 3 |
| Acute kidney injury | 3 |
| Prerenal failure | 2 |
| End stage renal disease | 1 |
| Hyperkalaemia | 23 |
| Blood potassium increased | 4 |
| Hyperkalaemia | 13 |
| Muscle spasms | 6 |
| Dehydration | 17 |
| Dehydration | 16 |
| Weight decreased | 2 |
| Thrombosis and thromboembolism | 7 |
| Cerebellar infarction | 1 |
| Cerebral infarction | 2 |
| Disseminated intravascular coagulation | 1 |
| Pulmonary embolism | 2 |
| Retinal artery occlusion | 1 |